This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/chemspider/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n6http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n4http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/kegg-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB04831/identifier/bindingdb/

Statements

Subject Item
n2:DB04831
rdf:type
n6:Drug
n6:description
Ticrynafen, or tienilic acid, is a diuretic drug with uric acid-lowering (uricosuric) action, formerly marketed for the treatment of hypertension. It was withdrawn in 1982, shortly after its introduction to the market, after case reports in the United States indicated a link between the use of ticrynafen and hepatitis. (Manier et al., 1982)
n6:generalReferences
# Manier JW, Chang WW, Kirchner JP, Beltaos E: Hepatotoxicity associated with ticrynafen--a uricosuric diuretic. Am J Gastroenterol. 1982 Jun;77(6):401-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7091125
n6:group
withdrawn
n6:indication
For the treatment of hypertension.
owl:sameAs
n9:DB04831 n10:DB04831
dcterms:title
Ticrynafen
adms:identifier
n4:C11702 n5:Ticrynafen n13:50090674 n14:35204 n16:46505485 n17:D02386 n18:38409 n19:DB04831
n6:synonym
(2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid Acidum tienilicum (2,3-Dichloro-4-(2-thiophenecarbonyl)phenoxy)acetic acid Tienilic acid Thienylic acid 4-(2-Thienylketo)-2,3-dichlorophenoxyacetic acid (2,3-Dichloro-4-(2-thienylcarbonyl)phenoxy)acetic acid Acide tienilique Acido tienilico 4-(2-Theonyl)-2,3-dichlorphenoxyessigsaeure Tienilico acido
n6:synthesisReference
Harold Graboyes, "Method for preparing ticrynafen." U.S. Patent US4107179, issued April, 1977.
n11:hasConcept
n12:M0021527
n6:IUPAC-Name
n7:271B57C6-363D-11E5-9242-09173F13E4C5
n6:InChI
n7:271B57CC-363D-11E5-9242-09173F13E4C5
n6:Molecular-Formula
n7:271B57CB-363D-11E5-9242-09173F13E4C5
n6:Molecular-Weight
n7:271B57C8-363D-11E5-9242-09173F13E4C5
n6:Monoisotopic-Weight
n7:271B57C9-363D-11E5-9242-09173F13E4C5
n6:SMILES
n7:271B57CA-363D-11E5-9242-09173F13E4C5
n6:Water-Solubility
n7:271B57C4-363D-11E5-9242-09173F13E4C5
n6:logP
n7:271B57C5-363D-11E5-9242-09173F13E4C5 n7:271B57C2-363D-11E5-9242-09173F13E4C5
n6:logS
n7:271B57C3-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Acceptor-Count
n7:271B57D2-363D-11E5-9242-09173F13E4C5
n6:H-Bond-Donor-Count
n7:271B57D3-363D-11E5-9242-09173F13E4C5
n6:InChIKey
n7:271B57CD-363D-11E5-9242-09173F13E4C5
n6:Polar-Surface-Area--PSA-
n7:271B57CE-363D-11E5-9242-09173F13E4C5
n6:Polarizability
n7:271B57D0-363D-11E5-9242-09173F13E4C5
n6:Refractivity
n7:271B57CF-363D-11E5-9242-09173F13E4C5
n6:Rotatable-Bond-Count
n7:271B57D1-363D-11E5-9242-09173F13E4C5
n6:affectedOrganism
Humans and other mammals
n6:casRegistryNumber
40180-04-9
n6:category
n6:Bioavailability
n7:271B57D8-363D-11E5-9242-09173F13E4C5
n6:Ghose-Filter
n7:271B57DA-363D-11E5-9242-09173F13E4C5
n6:MDDR-Like-Rule
n7:271B57DB-363D-11E5-9242-09173F13E4C5
n6:Melting-Point
n7:271B57DC-363D-11E5-9242-09173F13E4C5
n6:Number-of-Rings
n7:271B57D7-363D-11E5-9242-09173F13E4C5
n6:Physiological-Charge
n7:271B57D6-363D-11E5-9242-09173F13E4C5
n6:Rule-of-Five
n7:271B57D9-363D-11E5-9242-09173F13E4C5
n6:Traditional-IUPAC-Name
n7:271B57C7-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-acidic-
n7:271B57D4-363D-11E5-9242-09173F13E4C5
n6:pKa--strongest-basic-
n7:271B57D5-363D-11E5-9242-09173F13E4C5